Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10PITTSBURGH, Feb. 20, 2024 (GLOBE…
Significant efforts lie ahead, as the Black Book survey reveals that only 37% of medical practice respondents are receiving value-based…
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose…
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical…
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole…
STUDIO CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to announce the launch…
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review…
- Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar…
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional…
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and…